<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32198305</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>19</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>e035080</StartPage><MedlinePgn>e035080</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e035080</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2019-035080</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Due to the anti-inflammatory, antioxidant and anti-apoptotic properties of minocycline, clinical trials have evaluated the potential of this drug to treat several psychiatric and neurological disorders, including major depressive disorder, schizophrenia, bipolar disorder, stroke and amyotrophic lateral sclerosis. This protocol proposes a systematic review (and potential meta-analysis) that aims to identify and critically evaluate randomised controlled trials of minocycline for treating psychiatric and neurological disorders.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">PubMed, Embase, Cochrane Central Register of Controlled Clinical Trials, PsycINFO and Cumulative Index to Nursing and Allied Health Literature (CINAHL) will be used to identify randomised controlled trials that used minocycline to treat psychiatric and neurological disorders. Double-blind, randomised, controlled, clinical trials of participants aged 18 years or older and written in English will be included in the review. Data will be extracted by two independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines will be followed and the Cochrane Collaboration's 'Risk of Bias' tool will be used to assess the risk of bias in all studies included in the systematic review. The Grading of Recommendations, Assessment, Development and Evaluation system will be used to access the overall quality of the level of evidence of the studies. If sufficient evidence is identified, a meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. Heterogeneity of evidence will be evaluated using the I<sup>2</sup> model.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">This systematic review will evaluate only published data; therefore, ethical approval is not required. The systematic review will be published in a peer-reviewed journal and presented at relevant research conferences.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">CRD42020153292.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bortolasci</LastName><ForeName>Chiara C</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-0794-6363</Identifier><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia bchiara@deakin.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marx</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasebe</LastName><ForeName>Kyoko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medical Sciences, UNSW Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kavanagh</LastName><ForeName>Bianca E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Margaret J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>School of Medical Sciences, UNSW Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohebbi</LastName><ForeName>Mohammadreza</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biostatistics Unit, Faculty of Health, Deakin University, Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Alyna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle &amp; Hunter Medical Research Institute, Callaghan, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Lesley</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Melbourne School of Population and Global Health, University of Melbourne, Carlton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walder</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dean</LastName><ForeName>Olivia M</ForeName><Initials>OM</Initials><AffiliationInfo><Affiliation>The Institute for Mental and Physical Health and Clinical Translation, Deakin University, Barwon Health, Geelong, Victoria, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000975">Antioxidants</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYY3R43WGO</RegistryNumber><NameOfSubstance UI="D008911">Minocycline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="Y">Anti-Inflammatory Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000975" MajorTopicYN="Y">Antioxidants</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008911" MajorTopicYN="Y">Minocycline</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000078202" MajorTopicYN="N">Systematic Reviews as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">neurology</Keyword><Keyword MajorTopicYN="N">protocols &amp; guidelines</Keyword><Keyword MajorTopicYN="N">psychiatry</Keyword></KeywordList><CoiStatement>Competing interests: OMD has received grant support from the Brain and Behavior Foundation, Simons Autism Foundation, Stanley Medical Research Institute, Deakin University, Lilly, National Health and Medical Research Council (NHMRC) and Australasian Society for Bipolar and Depressive Disorders/Servier. MJM has received grant support from NHMRC.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32198305</ArticleId><ArticleId IdType="pmc">PMC7103827</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2019-035080</ArticleId><ArticleId IdType="pii">bmjopen-2019-035080</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nagarakanti S, Bishburg E. Is minocycline an antiviral agent? A review of current literature. Basic Clin Pharmacol Toxicol 2016;118:4&#x2013;8. 10.1111/bcpt.12444</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.12444</ArticleId><ArticleId IdType="pubmed">26177421</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232&#x2013;60. 10.1128/MMBR.65.2.232-260.2001</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.65.2.232-260.2001</ArticleId><ArticleId IdType="pmc">PMC99026</ArticleId><ArticleId IdType="pubmed">11381101</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner SE, Eady A, Bennett C, et al. . Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2012:Cd002086. 10.1002/14651858.CD002086.pub2</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD002086.pub2</ArticleId><ArticleId IdType="pmc">PMC7017847</ArticleId><ArticleId IdType="pubmed">22895927</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens V, Regen F, Le Bret N, et al. . Anti-Inflammatory effects of minocycline are mediated by retinoid signaling. BMC Neurosci 2018;19:58. 10.1186/s12868-018-0460-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-018-0460-x</ArticleId><ArticleId IdType="pmc">PMC6151010</ArticleId><ArticleId IdType="pubmed">30241502</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrido-Mesa N, Zarzuelo A, G&#xe1;lvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol 2013;169:337&#x2013;52. 10.1111/bph.12139</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12139</ArticleId><ArticleId IdType="pmc">PMC3651660</ArticleId><ArticleId IdType="pubmed">23441623</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean OM, Data-Franco J, Giorlando F, et al. . Minocycline: therapeutic potential in psychiatry. CNS Drugs 2012;26:391&#x2013;401. 10.2165/11632000-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11632000-000000000-00000</ArticleId><ArticleId IdType="pubmed">22486246</ArticleId></ArticleIdList></Reference><Reference><Citation>Data-Franco J, Singh A, Popovic D, et al. . Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology. Prog Neuropsychopharmacol Biol Psychiatry 2017;72:73&#x2013;86. 10.1016/j.pnpbp.2016.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2016.09.004</ArticleId><ArticleId IdType="pubmed">27616052</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson G, Berk M, Dean O, et al. . Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: therapeutic implications. CNS Drugs 2014;28:1&#x2013;10. 10.1007/s40263-013-0119-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40263-013-0119-1</ArticleId><ArticleId IdType="pubmed">24150993</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandaker GM, Cousins L, Deakin J, et al. . Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015;2:258&#x2013;70. 10.1016/S2215-0366(14)00122-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(14)00122-9</ArticleId><ArticleId IdType="pmc">PMC4595998</ArticleId><ArticleId IdType="pubmed">26359903</ArticleId></ArticleIdList></Reference><Reference><Citation>Spangenberg EE, Green KN. Inflammation in Alzheimer's disease: lessons learned from microglia-depletion models. Brain Behav Immun 2017;61:1&#x2013;11. 10.1016/j.bbi.2016.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.07.003</ArticleId><ArticleId IdType="pmc">PMC5218993</ArticleId><ArticleId IdType="pubmed">27395435</ArticleId></ArticleIdList></Reference><Reference><Citation>R&#xe9;us GZ, Fries GR, Stertz L, et al. . The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015;300:141&#x2013;54. 10.1016/j.neuroscience.2015.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.05.018</ArticleId><ArticleId IdType="pubmed">25981208</ArticleId></ArticleIdList></Reference><Reference><Citation>Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation 2018;15:144. 10.1186/s12974-018-1192-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1192-7</ArticleId><ArticleId IdType="pmc">PMC5952578</ArticleId><ArticleId IdType="pubmed">29764485</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraus RL, Pasieczny R, Lariosa-Willingham K, et al. . Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005;94:819&#x2013;27. 10.1111/j.1471-4159.2005.03219.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03219.x</ArticleId><ArticleId IdType="pubmed">16033424</ArticleId></ArticleIdList></Reference><Reference><Citation>Soory M. A role for non-antimicrobial actions of tetracyclines in combating oxidative stress in periodontal and metabolic diseases: a literature review. Open Dent J 2008;2:5&#x2013;12. 10.2174/1874210600802010005</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874210600802010005</ArticleId><ArticleId IdType="pmc">PMC2581528</ArticleId><ArticleId IdType="pubmed">19088876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Huang P, Chen H, et al. . The inhibitory effect of minocycline on radiation-induced neuronal apoptosis via AMPK&#x3b1;1 signaling-mediated autophagy. Sci Rep 2017;7:16373. 10.1038/s41598-017-16693-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-16693-8</ArticleId><ArticleId IdType="pmc">PMC5703722</ArticleId><ArticleId IdType="pubmed">29180765</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Wei Q, Wang C-Y, et al. . Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. J Biol Chem 2004;279:19948&#x2013;54. 10.1074/jbc.M313629200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M313629200</ArticleId><ArticleId IdType="pubmed">15004018</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Y, Giri PK, Lei S, et al. . Pretreatment with minocycline restores neurogenesis in the subventricular zone and subgranular zone of the hippocampus after ketamine exposure in neonatal rats. Neuroscience 2017;352:144&#x2013;54. 10.1016/j.neuroscience.2017.03.057</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2017.03.057</ArticleId><ArticleId IdType="pubmed">28391017</ArticleId></ArticleIdList></Reference><Reference><Citation>Miao H, Li R, Han C, et al. . Minocycline promotes posthemorrhagic neurogenesis via M2 microglia polarization via upregulation of the TrkB/BDNF pathway in rats. J Neurophysiol 2018;120:1307&#x2013;17. 10.1152/jn.00234.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.00234.2018</ArticleId><ArticleId IdType="pubmed">29790836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W, Zhu X-M, Zhang Q-E, et al. . Adjunctive minocycline for major mental disorders: a systematic review. J Psychopharmacol 2019;33:1215&#x2013;26. 10.1177/0269881119858286</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269881119858286</ArticleId><ArticleId IdType="pubmed">31294649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J Affect Disord 2018;227:219&#x2013;25. 10.1016/j.jad.2017.10.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2017.10.042</ArticleId><ArticleId IdType="pubmed">29102836</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Y-Q, Zheng W, Wang S-B, et al. . Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol 2017;27:8&#x2013;18. 10.1016/j.euroneuro.2016.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euroneuro.2016.11.012</ArticleId><ArticleId IdType="pubmed">27919523</ArticleId></ArticleIdList></Reference><Reference><Citation>Solmi M, Veronese N, Thapa N, et al. . Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia. CNS Spectr 2017;22:415&#x2013;26. 10.1017/S1092852916000638</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1092852916000638</ArticleId><ArticleId IdType="pubmed">28181901</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhotra K, Chang JJ, Khunger A, et al. . Minocycline for acute stroke treatment: a systematic review and meta-analysis of randomized clinical trials. J Neurol 2018;265:1871&#x2013;9. 10.1007/s00415-018-8935-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8935-3</ArticleId><ArticleId IdType="pubmed">29948247</ArticleId></ArticleIdList></Reference><Reference><Citation>Diguet E, Fernagut P-O, Wei X, et al. . Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 2004;19:3266&#x2013;76. 10.1111/j.0953-816X.2004.03372.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0953-816X.2004.03372.x</ArticleId><ArticleId IdType="pubmed">15217383</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MA, Mallien AS, Pfeiffer N, et al. . Minocycline does not evoke anxiolytic and antidepressant-like effects in C57BL/6 mice. Behav Brain Res 2016;301:96&#x2013;101. 10.1016/j.bbr.2015.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2015.12.015</ArticleId><ArticleId IdType="pubmed">26698398</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji M, Wilson MA, Lange MS, et al. . Minocycline worsens hypoxic-ischemic brain injury in a neonatal mouse model. Exp Neurol 2004;189:58&#x2013;65. 10.1016/j.expneurol.2004.01.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2004.01.011</ArticleId><ArticleId IdType="pubmed">15296836</ArticleId></ArticleIdList></Reference><Reference><Citation>Inta I, Vogt MA, Vogel AS, et al. . Minocycline exacerbates apoptotic neurodegeneration induced by the NMDA receptor antagonist MK-801 in the early postnatal mouse brain. Eur Arch Psychiatry Clin Neurosci 2016;266:673&#x2013;7. 10.1007/s00406-015-0649-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-015-0649-2</ArticleId><ArticleId IdType="pubmed">26482736</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong VW, Wells J, Giuliani F, et al. . The promise of minocycline in neurology. Lancet Neurol 2004;3:744&#x2013;51. 10.1016/S1474-4422(04)00937-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(04)00937-8</ArticleId><ArticleId IdType="pubmed">15556807</ArticleId></ArticleIdList></Reference><Reference><Citation>Shamseer L, Moher D, Clarke M, et al. . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647. 10.1136/bmj.g7647</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.g7647</ArticleId><ArticleId IdType="pubmed">25555855</ArticleId></ArticleIdList></Reference><Reference><Citation>Innovation VH 
Covidence systematic review software. Available: www.covidence.org</Citation></Reference><Reference><Citation>Higgins JPT, Altman DG, G&#xf8;tzsche PC, et al. . The Cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. 10.1136/bmj.d5928</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d5928</ArticleId><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, et al. . Grade: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924&#x2013;6. 10.1136/bmj.39489.470347.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) [Computer program. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.</Citation></Reference><Reference><Citation>Higgins JPT. Cochrane Handbook for systematic reviews of interventions version 5.1.0: the Cochrane collaboration, 2011.</Citation></Reference><Reference><Citation>Moher D, Shamseer L, Clarke M, et al. . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1. 10.1186/2046-4053-4-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId><ArticleId IdType="pmc">PMC4320440</ArticleId><ArticleId IdType="pubmed">25554246</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>